{
  "id": 18605293,
  "title": "South African trial tests off-the-shelf killer cells against lymphoma",
  "url": "https://urgent.news/2026/11/07/south-african-trial-tests-off-the-shelf-killer-cells-against-lymphoma",
  "topic": "science",
  "section": "Science",
  "published": "2026-11-07T00:40:01.000Z",
  "source": {
    "name": "Medical Xpress",
    "slug": "medical-xpress",
    "url": "https://medicalxpress.com/news/2026-11-south-african-trial-shelf-killer.html"
  },
  "original_language": "en",
  "account": "Researchers in South Africa are conducting an off-the-shelf immune cell trial against lymphoma, an approach that avoids the need to manufacture a separate treatment for each patient's cells. The trial uses genetically engineered natural killer (NK) cells derived from a shared laboratory cell line. Dr. Jackie Thomson, a clinical hematologist and stem cell transplant specialist, combines this research with teaching doctors to deliver complex blood cancer care. The study, QUILT-106, focuses on selected B-cell non-Hodgkin lymphomas and tests the engineered cells alone and with rituximab, another antibody treatment. The phase 1 study concentrates on safety and tolerability while looking for early signs of a response. The cells are produced from an established cell line and imported for the South African study, avoiding the need to collect and genetically modify each patient's own immune cells. Thomson believes these cells could be cheaper in the long run due to simplified logistics and reduced costs. The need for blood cancer care is significant in South Africa, with 2,342 new non-Hodgkin lymphoma cases and 1,428 leukemia cases recorded in 2024. Delivering advanced treatments requires a well-equipped infrastructure, including centers for patient assessment, cell product handling, and recovery monitoring. Thomson established the transplant unit in 2019 and achieved JACIE accreditation in 2025, which certifies compliance with international standards. Residents rotate through the unit to learn about transplant planning and monitoring, ensuring they gain expertise in interpreting bone marrow findings, selecting donors, and managing complications during and after the transplant. The trial has yet to determine affordability, and more research is needed to establish which patients might benefit and whether responses last.",
  "summary": "South African researchers are testing \"off-the-shelf\" immune cells against lymphoma that has returned or resisted treatment, investigating an approach that avoids having to manufacture a separate treatment from each patient's own cells.",
  "key_points": [
    "South African trial tests off-the-shelf NK cells for lymphoma treatment.",
    "QUILT-106 study examines engineered NK cells alone and with rituximab.",
    "Trial focuses on B-cell non-Hodgkin lymphomas, prioritizing safety and tolerability."
  ],
  "editors_take": "Utilizing shared laboratory cell lines instead of patient-specific manufacturing simplifies logistics and offers a potential pathway toward lowering the long-term costs of advanced blood cancer treatments in South Africa.",
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}